Abstract
Phosphodiesterases (PDEs) are the only known enzymes to degrade intracellular cyclic AMP and/or cyclic GMP. The PDE superfamily consists of 11 families (PDE1– PDE11), each of which has 1 to 4 subtypes. Some of the subtypes may have multiple splice variants (e.g. PDE4D1–PDE4D11), leading to a total of more than 100 known proteins to date. Growing attention has been paid to the potential of PDEs as therapeutic targets for mood disorders and/or diseases affecting cognitive activity by controlling the rate of hydrolysis of the two aforementioned second messengers in recent years. The loss of cognitive functions is one of the major complaints most patients with CNS diseases face; it has an even more prominent negative impact on the quality of daily life. Cognitive dysfunction is usually a prognosis in patients suffering from neuropsychiatric and neurodegenerative diseases, including depression, schizophrenia, and Alzheimer’s disease. This review will focus on the contributions of PDEs to the interface between cognitive deficits and neuropsychiatric and neurodegenerative disorders. It is expected to make for the understanding and discovery that selective PDE inhibitors have the therapeutic potential for cognitive dysfunctions associated with neuropsychiatric and neurodegenerative disorders.
Keywords: Phosphodiesterase, cognitive deficit, neuropsychiatric disease, neurodegenerative diseases, cyclic AMP, cyclic GMP, PDE4 subtype, splice variant.
Current Pharmaceutical Design
Title:Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Volume: 21 Issue: 3
Author(s): Zhen-Zhen Wang, Yi Zhang, Han-Ting Zhang and Yun-Feng Li
Affiliation:
Keywords: Phosphodiesterase, cognitive deficit, neuropsychiatric disease, neurodegenerative diseases, cyclic AMP, cyclic GMP, PDE4 subtype, splice variant.
Abstract: Phosphodiesterases (PDEs) are the only known enzymes to degrade intracellular cyclic AMP and/or cyclic GMP. The PDE superfamily consists of 11 families (PDE1– PDE11), each of which has 1 to 4 subtypes. Some of the subtypes may have multiple splice variants (e.g. PDE4D1–PDE4D11), leading to a total of more than 100 known proteins to date. Growing attention has been paid to the potential of PDEs as therapeutic targets for mood disorders and/or diseases affecting cognitive activity by controlling the rate of hydrolysis of the two aforementioned second messengers in recent years. The loss of cognitive functions is one of the major complaints most patients with CNS diseases face; it has an even more prominent negative impact on the quality of daily life. Cognitive dysfunction is usually a prognosis in patients suffering from neuropsychiatric and neurodegenerative diseases, including depression, schizophrenia, and Alzheimer’s disease. This review will focus on the contributions of PDEs to the interface between cognitive deficits and neuropsychiatric and neurodegenerative disorders. It is expected to make for the understanding and discovery that selective PDE inhibitors have the therapeutic potential for cognitive dysfunctions associated with neuropsychiatric and neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Wang Zhen-Zhen, Zhang Yi, Zhang Han-Ting and Li Yun-Feng, Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases, Current Pharmaceutical Design 2015; 21 (3) . https://dx.doi.org/10.2174/1381612820666140826115559
DOI https://dx.doi.org/10.2174/1381612820666140826115559 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Flavonoids in the Treatment of Alzheimer’s and Other Neurodegenerative Diseases
Current Medicinal Chemistry Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia
Current HIV Research Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Fuzzy Computer-Aided Alzheimer’s Disease Diagnosis Based on MRI Data
Current Alzheimer Research New Directions for Dementia
Current Neurovascular Research Stress and the α7 Nicotinic Acetylcholine Receptor
Current Drug Targets Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Effect of Cholinergic Stimulation in Early Alzheimers Disease - Functional Imaging During a Recognition Memory Task
Current Alzheimer Research Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets